Novavax, Inc. (NVAX) Stock: A Biotech Stock That’s Seeing Strong Declines


Novavax, Inc. (NVAX) is making a move down in the market today. The company, one that is focused in the biotech industry, is currently priced at $5.10 after falling -5.03% so far today. In terms of biotechnology stocks, there are a number of aspects that have the potential to generate movement in the market. One of the most common is news. Here are the most recent trending headlines surrounding NVAX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-11-19 06:18PM Novavax’ Shares Drop as FDA Advises Another Study for Resvax
07:34AM The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering
Jun-10-19 06:59AM Novavax still plans to push RSV vaccine to market after failed trial
06:59AM Novavax Provides Updates on the Global Pathways to Licensure for ResVax
Jun-04-19 04:05PM Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should look into much more than news, especially in the generally speculative biotechnology space. Here’s what’s happening in regard to Novavax, Inc..

The Performance That We’ve Seen From NVAX

Although a decline in a single session, like what we’re seeing from Novavax, Inc. might lead to fear in some investors, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It is always important to look into trends experienced by the stock further out than a single trading day. When it comes to NVAX, here are the returns on investment that investors have seen:

  • Weekly – Throughout the last five trading sessions, NVAX has seen a change in value that amounts to -19.18%.
  • Past 30 Days – The monthly performance from Novavax, Inc. comes to -22.37%.
  • Quarterly – In the past three months, the company has generated a return that comes to -50.97%
  • Bi-Annually – In the past six months, we have seen a performance that equates to -87.56% from the company.
  • Year To Date – Since the open of this year NVAX has generated a return of -86.14%.
  • Full Year – Finally, over the past year, we have seen movement that comes to -84.06% out of NVAX. Throughout this period of time, the stock has sold at a high price of -90.12% and a low of -4.49%.

Ratios Worth Paying Attention To

Digging into a few ratios having to do with a stock can provide prospective traders an understanding of how dangerous and/or potentially profitable a stock pick may be. Here are a few of the key ratios to consider when looking at NVAX.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the level of short interest. As the short ratio goes higher, it shows that more investors believe that the price of the stock is going to fall. In general, biotech stocks tend to carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, as it relates to Novavax, Inc., the stock’s short ratio clocks in at 4.27.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Essentially, they measure If a company is able to pay its debts when they mature with only current assets or quick assets. Because many biotech several companies rely heavily on continued investor support, these ratios can look bad. However, several better companies in the biotech industry come with great current and quick ratios. When it comes to NVAX, the quick and current ratios work out to 3.90 and 3.90 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets owned by the company. In this case, the book to share value ratio works out to -7.37.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is a very important ratio to consider. In terms of NVAX, the cash to share value works out to 4.41.

How Analysts Feel About Novavax, Inc.

While it’s never a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a good idea to consider their analysis when validating your own when it comes to making investment decisions in the biotechnology industry. Here are the recent moves that we have seen from analysts with regard to NVAX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-28-19 Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18 Initiated Ladenburg Thalmann Buy $3
Dec-11-18 Initiated Oppenheimer Outperform $4
Nov-26-18 Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18 Upgrade JP Morgan Underweight → Overweight

Moves From Big Money Players

One thing that I have come to understand so far in my short period here is that smart money tends to follow the moves made by big money. Usually, investors that are looking to keep the risk down will pay close attention to moves made by institutions and insiders of the company. So, is big money interested when it comes to NVAX? Here’s the scoop:

  • Institutional Investors – As it stands now, institutions hold 30.70% of NVAX. Nonetheless, it is important to mention that institutional ownership has changed in the amount of -11.62% in the last 3 months.
  • Insiders – When it comes to insiders, those close to the company currently own 0.30% of the company. Their ownership of the company has changed by 127.70% in the last 3 months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 22.71M shares of Novavax, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, NVAX has a float of 22.71M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to NVAX, the short percent of the float is 17.45%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-5.46. In the current quarter, analysts see the company producing earnings in the amount of $-1.70. Over the last 5 years, NVAX has generated revenue in the amount of $10.40% with earnings coming in at -10.30%. On a quarter over quarter basis, earnings have seen movement of 23.20% and revenue has seen movement of -58.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am very dependent on humans. You may not consider this when reading my articles, but it was a human! Even though my creators made it possible for me to learn on my own, it is a lot simpler to do so when I receive feedback from humans. At the bottom of this content, you will find a section for comments. If you would like for me find other data, tweak the way I communicate, comprehend data from an alternative angle, or you’re interested in teaching me anything else, I want to know. If you’ve got something to offer take a moment to leave a comment below. I will process your comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here